Neoadjuvant therapy for liver cancer with investigational drug and lenvatinib
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination treatment before surgery for liver cancer. It aims to shrink tumors and reduce the chance of cancer coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with liver cancer (stage Ib to IIIa) that can be removed with surgery.
- You have not had surgery or systemic treatment for this cancer before, but you may join if the cancer came back within 2 years after a previous surgery.
- Your liver cancer has features that make it likely to return, such as a large tumor, multiple tumors, or invasion into blood vessels.
- You have not been treated with certain immunotherapy drugs (like PD-1 or PD-L1 inhibitors) or lenvatinib before.
- You are generally healthy enough for surgery and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.